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Abstract
Background: Low concentrations of local anesthetics (LAs) suppress cellular excitability by inhibiting voltage-gated Na
+ channels. In contrast, LAs at high concentrations can be excitatory and neurotoxic. We recently demonstrated that LA-
evoked activation of sensory neurons is mediated by the capsaicin receptor TRPV1, and, to a lesser extent by the irritant
receptor TRPA1. LA-induced activation and sensitization of TRPV1 involves a domain that is similar, but not identical to
the vanilloid-binding domain. Additionally, activation of TRPV1 by LAs involves PLC and PI(4,5)P2-signalling. In the
present study we aimed to characterize essential structural determinants for LA-evoked activation of TRPA1.
Results: Recombinant rodent and human TRPA1 were expressed in HEK293t cells and investigated by means of
whole-cell patch clamp recordings. The LA lidocaine activates TRPA1 in a concentration-dependent manner. The
membrane impermeable lidocaine-derivative QX-314 is inactive when applied extracellularly. Lidocaine-activated
TRPA1-currents are blocked by the TRPA1-antagonist HC-030031. Lidocaine is also an inhibitor of TRPA1, an effect
that is more obvious in rodent than in human TRPA1. This species-specific difference is linked to the pore region
(transmembrane domain 5 and 6) as described for activation of TRPA1 by menthol. Unlike menthol-sensitivity
however, lidocaine-sensitivity is not similarly determined by serine- and threonine-residues within TM5. Instead,
intracellular cysteine residues known to be covalently bound by reactive TRPA1-agonists seem to mediate
activation of TRPA1 by LAs.
Conclusions: The structural determinants involved in activation of TRPA1 by LAs are disparate from those involved
in activation by menthol or those involved in activation of TRPV1 by LAs.
Background
LAs are well established in clinical practice and their use is
accompanied by a low prevalence of severe side effects.
However, it is well documented that intrathecal and peri-
neural application of highly concentrated LAs can be neu-
rotoxic and induce sequelae such as transient neurological
symptoms and the cauda equina syndrome [1-4]. Several
cellular mechanisms have been suggested to mediate LA-
induced neurotoxicity. The most recent reports suggest
that LAs can induce both necrosis and apoptosis [5-9]. In
dorsal root ganglion (DRG) neurons, lidocaine-induced
cell death was also reported to be associated with a Ca
2
+-influx and a depolarization [10]. Moreover, recent stu-
dies propose that LAs can enhance a release of
neuropeptides when applied into surgical wounds and
induce a release of glutamate from central sensory term-
inals when applied intrathecally [11,12]. Accordingly, the
local injection of most clinically established formulations
of local anesthetics is accompanied by a brief, but discom-
forting burning sensation [13,14]. Our laboratory recently
reported that LAs directly activate the capsaicin receptor
TRPV1 and evoke a TRPV1-dependent release of neuro-
peptides from mouse skin and from isolated peripheral
nerves [15]. TRPV1 is selectively expressed in nociceptive
sensory neurons where it acts as a polymodal membrane
receptor for noxious heat and various chemical insults
[16,17]. The pore of TRPV1 displays an unselective perme-
ability for mono- and divalent cations, but is also perme-
able for large molecules such as the lidocaine derivative
QX-314 [18,19]. Due to this property, TRPV1 can mediate
neurotoxicity by mechanisms involving an intracellular
Ca
2+-overload and a consecutive apoptosis or necrosis
[20,21]. Thus TRPV1 is a candidate mediator of LA-
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peptides [15]. However, LAs also evoke a TRPV1-indepen-
dent activation of a subpopulation of sensory neurons that
is due to activation of the irritant receptor TRPA1 [15].
Furthermore, Piao and colleagues suggested that LA-
induced release of glutamate from central sensory term-
inals is mediated by TRPA1 rather than by TRPV1 [11]. In
this study we therefore aimed to validate and further
characterize the effects of LAs on TRPA1 by means of
conventional whole-cell patch clamp recordings on
recombinant rodent and human TRPA1.
Results
HEK293t cells expressing wildtype rat TRPA1 (rTRPA1)
were examined by standard whole cell voltage-clamp
recordings (Vh -60 mV). As demonstrated in Figure 1A,
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Figure 1 Lidocaine activates and blocks rat TRPA1. A. Representative inward currents in HEK293t cells expressing rTRPA1 activated by 30 mM
lidocaine and 100 μM mustard oil. Cells were held at -60 mV. B- C. Concentration dependent activation of rTRPA1 by lidocaine. Only one
concentration was applied on each cell. The Hill-equation was applied to calculate the EC50 value. D. A typical example of a lidocaine-evoked
current blocked by the selective TRPA1-anatagonist HC-030331 (100 μM). E. Ramp currents of rTRPA1 in control solution and during application
of 30 mM lidocaine. Cells were held at -60 mV and currents were measured during 500 ms long voltage-ramps from -100 to +100 mV. Note the
lack of an outward rectification of the lidocaine-evoked current F. Representative effects on rTRPA1 30 mM lidocaine in cells held at +60 mV..G.
Typical MO-evoked inward current blocked by 100 mM lidocaine. Increasing concentrations of lidocaine were co-applied with MO during the
steady-state phase of MO-evoked currents. Experiments were performed in a Ca
2+-free extracellular solution to minimize desensitization. The
fractional block was plotted against the lidocaine concentration. The line represents the fit of the data to the Hill equation. H. Representative
currents of TRPA1-currents activated by three consecutive applications of 30 mM lidocaine in standard extracellular solution containing 2 mM
Ca
2+. Lidocaine was applied in intervals of 2 min. I. Mean current amplitudes of rTRPA1 currents evoked by repeated applications of lidocaine in
standard extracellular solution containing 2 mM Ca
2+ or in a Ca
2+-free solution. Current amplitudes are normalized to the value obtained with
the first application of lidocaine (dotted line).
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Page 2 of 9the LA lidocaine (30 mM) activates inward currents in
these cells being also activated by the TRPA1-agonist
mustard oil (MO, 100 μM). This lidocaine-evoked acti-
vation of rTRPA1 is concentration-dependent as
demonstrated by increasing peak amplitudes of currents
evoked by 3 mM (432 ± 104 pA, n = 6), 10 mM (2211
± 483 pA, n = 8) and 30 mM (2690 ± 668 pA, n = 8).
At 100 mM however, lidocaine evokes rapidly inactivat-
ing currents which are generally smaller (1169 ± 257
pA, n = 8) than those activated by 30 mM (Figure 1B).
The calculated EC50-value of lidocaine-evoked activation
of rTRPA1 is 5.7 ± 0.2 mM (Figure 1C, Hill-equation, n
= 22). Importantly, non-transfected cells do not produce
any lidocaine-evoked inward currents in concentrations
up to 100 mM. Moreover, hyperosmolaric solutions
containing glucose up to a concentration of 130 mM
did not evoke any activation of rTRPA1 (n = 5, data not
shown). The TRPA1-inhibitor HC-030031 (100 μM)
blocks lidocaine-induced rTRPA1-currents (by 64 ± 5%,
n = 5, Figure 1D). Furthermore, rTRPA1 is also acti-
vated by the local anesthetics mepivacaine and procaine
(30 mM in each case, data not shown). Notably, the
inward currents evoked by 30 and 100 mM lidocaine
display large resurging currents following washout of
lidocaine (Figure 1B). rTRPA1 also exhibits a less pro-
nounced outward-rectification in presence of 30 mM
lidocaine as compared to control solution during 500
ms-long voltage-ramps from -100 to +100 mV (Figure
1E). Furthermore, 30 mM lidocaine failed to evoke out-
ward currents in cells held at +60 mV, however pro-
duced large resurging outward current following
washout (Figure 1F). These data are reminiscent of a
bimodal effect of lidocaine on TRPA1, as was also
described for TRPV1 [15]. As demonstrated in Figure
1G, lidocaine blocked TRPA1-mediated currents acti-
vated by mustard oil (100 μM). This block displays a
rapid onset, is reversible upon washout of lidocaine and
is concentration dependent (Figure 1G, IC50-value 25 ±
3 mM, n = 4- 5 for each concentration). Other studies
s u g g e s tt h a tt h ed i l a t e dp o r es t a t eo fT R P A 1i sC a
2
+-dependent. Moreover, it is the dilated pore that
enables more efficient open channel block [22]. We
f o u n dt h a tb l o c ko fM O - e v o k e dc u r r e n t sb y3 0m M
lidocaine is comparable in the presence or absence of
extracellular Ca
2+. (data now shown). Thus, a dilated
pore is not a prerequisite for lidocaine-induced block of
mTRPA1.
We also observed a pronounced tachyphylaxis and
desensitization of lidocaine-evoked activation of rTRPA1
upon repetitive applications (Figure 1H). While a similar
tachyphylaxis and desensitization of LA-evoked TRPV1-
currents were found to be strongly enhanced in the
absence of extracellular calcium [15], the removal of
extracellular calcium rather seems to reduce this process
on rTRPA1 (Figure 1I, p < 0.05 for 2
nd application,
unpaired t-test).
We next examined the effects of lidocaine on human
TRPA1 (hTRPA1). Similar to rTRPA1, hTRPA1 is acti-
vated by lidocaine ≥ 3m M( 3m M3 6±8p A ,n=1 1 ;
10 mM 86 ± 12 pA; n = 9, 30 mM 1147 ± 266 pA, n =
18; 100 mM 1652 ± 541 pA, n = 10) with a calculated
EC50-value of 24.0 ± 0.6 mM (Figure 2A and 2B, Hill-
equation). Notably, the resurging current following
washout of lidocaine observed for rTRPA1 is completely
missing for hTRPA1 (Figure 2A). A similar species-spe-
cific effect on TRPA1 was recently reported for menthol,
i.e. menthol activates and blocks mouse TRPA1
(mTRPA1) while hTRPA1 is only activated [23]. This
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Figure 2 Lidocaine activates human TRPA1. A.R e p r e s e n t a t i v e
inward currents in HEK293t cells expressing hTRPA1 activated by 3,
10, 30 and 100 mM lidocaine. Cells were held at -60 mV and only
one concentration was applied on each cell. B. Concentration-
dependent activation of hTRPV1 by lidocaine. The Hill-equation was
applied to calculate the EC50 value. Transmembrane domain 5 is a
determinant for species different activation of TRPA1 by lidocaine C.
Representative inward currents evoked by 30 mM lidocaine on
mTRPA1-WT, and the chimeras mTRPA1-hTM5/6 and hTRPA1-mTM5/
6. Note the lack of a resurging current for mTRPA1-hTM5/6. D.
Typical experiments for lidocaine-induced block of MO-evoked
inward currents on hTRPA1-WT, mTRPA1-hTM5/6, mTRPA1-WT and
hTRPA1-mTM5/6. Lidocaine was co-applied with MO during the
steady-state phase of MO-evoked currents and experiments were
performed in a Ca
2+-free extracellular solution to minimize
desensitization. Note the slow onset of lidocaine-induced block for
hTRPA1-WT and mTRPA1-hTM5/6 as compared to mTRPA1-WT and
hTRPA1-mTM5/6. Cells were held at -60 mV.
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Page 3 of 9difference between mTRPA1 and hTRPA1 was linked to
transmembrane domain 5 (TM5) which was also sug-
gested to be a crucial interaction site for menthol-
evoked activation of TRPA1 [23]. We therefore asked if
lidocaine and menthol employ common mechanisms to
activate TRPA1. For this reason, we explored mutant
constructs of mouse and human TRPA1. Wildtype
mTRPA1, similar to rTRPA1, generates lidocaine-evoked
(30 mM) responses with resurging currents (1889 ± 742
pA, n = 9) (Figure 2C). The chimera mTRPA1-hTM5/6,
in which the region TM5 through TM6 of hTRPA1 was
introduced, similar to wildtype hTRPA1 generates lido-
caine-evoked currents without any resurging currents
(1095 ± 292 pA, n = 7). Accordingly, the reverse swap
of mTM5/6 into hTRPA1 results in small lidocaine-
evoked currents which are followed by prominent resur-
ging currents (54 ± 11 pA, n = 6) (Figure 2C). Consis-
tent with the hypothesis that the resurging current is a
result of a bimodal effect of lidocaine on TRPA1, MO-
activated currents of mTRPA1-WT and hTRPA1-
mTM5/6 are blocked by lidocaine (89 ± 4% block, n =
11 and 87 ± 5% block, n = 8, respectively) and show a
resurging current following washout of lidocaine. The
prominent effect of lidocaine on MO-activated currents
of hTRPA1-WT and mTRPA1-hTM5/6 however seems
to be an activation, followed by an acute desensitization
(Figure 2D and Additional file 1, figure s1). We next
examined if residues (S876/T877) within TM5, which
were demonstrated to be required for activation by
menthol [23], are also required for activation by lido-
caine. Surprisingly, the menthol-insensitive mutant
mTRPA1-S876V/T877L generates large lidocaine-evoked
inward currents with a mean current amplitude (582 ±
151 pA, n = 6, data not shown) not significantly smaller
than the mean current amplitude of mTRPA1-WT (p =
0.16, unpaired t-test). Thus, although menthol and lido-
caine interact with common sites within TM5, they
seem to employ distinct mechanisms to activate TRPA1.
We intended to test whether residues S876/T877 are
involved in the LA-evoked block of MO-activated
mTRPA1. Surprisingly, we found that 30 mM lidocaine
does not block MO-induced mTRPA1-S876V/T877L
currents but in contrast evoked an increase in the MO-
induced current followed by an acute desensitization
(Additional file 2, figure s2). A resurging current follow-
ing washout of lidocaine however suggests a bimodal
effect of lidocaine on mTRPA1-S876V/T877L. These
data indeed indicate that residues S876/T877 might be
involved in the LA-evoked block of mTRPA1, although
other sites might contribute as well. As the effect of
lidocaine on mTRPA1-S876V/T877L strongly resembles
the effect on hTRPA1, this result underlines the species-
specific involvement of transmembrane domains 5 and 6
in gating and blocking mechanisms of TRPA1.
We also asked if lidocaine and menthol exert similar
effects on the related menthol-sensitive receptor
TRPM8. As is demonstrated in Figure 3A, however,
lidocaine does not activate inward currents in HEK293t
cells expressing rat TRPM8. However, lidocaine acts as
blocker on rTRPM8 activated by menthol (Figure 3B,
IC50-value 8 ± 1 mM, n = 4- 7 for each concentration)
and by cold (Figure 3C, 64 ± 4% block by 30 mM lido-
caine, n = 6).
LAs activate TRPV1 via an intracellular pathway and
the intracellularly located capsaicin-binding domain
seems to be crucially involved in this process [15].
While the capsaicin-binding domain is not conserved in
TRPA1, intracellular cysteine residues have been
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Figure 3 Lidocaine blocks but does not activate TRPM8. A. Typical recordings on rTRPM8 with a completely lacking response to 30 mM
lidocaine but with a large inward current evoked by 100 μM menthol. Cells were held -60 mV B. Representative current trace displaying
lidocaine-induced block of a menthol-evoked inward current on rTRPM8. Lidocaine was co-applied with menthol during the steady-state phase
of menthol-evoked currents. The fractional block was plotted against the lidocaine concentration. The line represents the fit of the data to the
Hill equation. C. Cold-induced inward currents of rTRPM8 in control solution (black) or in presence of 30 mM lidocaine (grey). The applied
solution was cooled from room temperature (~ 24°C) to ~12°C within 10 seconds. Cells were held at -60 mV.
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Page 4 of 9suggested to be important interaction sites for reactive
TRPA1-agonists like mustard oil and acrolein [24,25]. In
order to examine whether LAs activate TRPA1 via intra-
cellular mechanisms, HEK293t cells expressing rTRPA1
were treated with 3 mM lidocaine at pH 6.9, 7.4 and 7.9
(Figure 4A). Lidocaine is a weak base with a pKa-value
of 7.9. While only 25% of the total lidocaine is mem-
brane-permeable at pH 7.4, the membrane-permeable
fraction is reduced to 10% at pH 6.9 and increased to
50% at pH 7.9. Compared to currents evoked by lido-
caine at pH 7.4, currents are smaller at pH 6.9 (0.8 ±
0.2-fold, n = 5) and significantly larger at pH 7.9 (5 ± 2-
fold, n = 5, p < 0.001, paired t-test) (Figure 4B). These
data imply that activation of TRPA1 requires membrane
permeability of lidocaine. Accordingly, the membrane
impermeable lidocaine derivative QX-314 (30 mM) does
not activate TRPA1 when applied extracellularly (Figure
4C, n = 5). We now wanted to find out whether LAs
indeed interact with the intracellular cysteine residues
C621, C641 and C665 of hTRPA1 as was previously
described for reactive TRPA1-agonists [25]. The triple
mutant hTRPA1-C621S/C641S/C665S (hTRPA1-3C) is
acrolein-insensitive but it still activated by carvacrol
(250 μM) (Figure 4D). We observed that in all hTRPA1-
3C HEK293t-cells generating robust carvacrol-evoked
currents (> 50 pA), currents evoked by 30 mM lidocaine
were very small (20 ± 8 pA, n = 11) (Figure 4D). As this
apparent reduction in lidocaine-sensitivity can be due to
a general loss of functionality of hTRPA1-3C, we com-
pared relative peak amplitudes evoked by lidocaine and
carvacrol (i.e. Iliodocaine/Icarvacrol)i nh T R P A 1 - 3 Ca n d
wildtype hTRPA1. As demonstrated in Figure 4E,
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Figure 4 Intracellular interaction sites of lidocaine on TRPA1. A. Current traces of wildtype rTRPA1 activated by 3 mM lidocaine at pH 6.9,
7.4 or 7.9. Lidocaine-solutions with different pH-values were applied on the same cells in intervals of 1 min. B. Relative current amplitudes of
rTRPA1 activated with 3 mM at different pH-values. The absolute current amplitudes were normalized to the amplitude determined for pH 7.4. C.
Typical effect of the impermeable lidocaine-derivative QX-314 on rTRPA1. 30 mM QX-314 did not evoke any current responses in TRPA1-
expressing HEK293t cells in which 30 mM lidocaine evoked large inward currents. Cells were held at -60 mV. D. Representative experiment
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Page 5 of 9the relative lidocaine-sensitivity of hTRPA1-3C
(Ilidocaine/Icarvacrol =7 . 5±2 . 3 % ,n=1 1 )i si n d e e ds i g n i f -
icantly reduced as compared to the wildtype construct
(Ilidocaine/Icarvacrol = 40.9 ± 4.7%, n = 10, Figure 4E) (p
< 0.001, unpaired t-test). To further test the function-
ality of hTRPA1-3C to other modes of activation, we
also investigate activation by 2-APB (2-Aminoethoxydi-
phenyl borate) and by voltage. As demonstrated by two
representative experiments in Figure 4F, both
hTRPA1-wildtype (n = 6) and hTRPA1-3C (n = 6) dis-
play robust outward currents when challenged with a
500 ms long voltage ramp from -100 mV to +100 mV.
Furthermore, 1 mM 2-APB activated currents with a
profound outward rectification on hTRPA1-wildtype
and hTRPA1-3C (Figure 4F). We thus can exclude a
loss of functionality of the mutant to activation by 2-
APB and voltage. These data thus indicate that lido-
caine indeed might interact with intracellular cysteines
to gate TRPA1, however, the residual lidocaine-sensi-
tivity of hTRPA1-3C suggests that further mechanisms
are involved in LA-induced activation.
There is strong evidence suggesting that intracellular
Ca
2+, increased by LA-mediated PLC activation, might
be a downstream signalling element of LA-evoked acti-
vation of TRPA1 [26,27]. For this reason, we have finally
tested the LA-sensitivity in a mutation within the N-
terminal EF-hand Ca
2+-binding domain, hTRPA1-
L474A. This mutation is insensitive to Ca
2+-dependent
modulation of agonist-induced responses, is insensitive
to icilin and renders TRPA1 insensitive to activation by
Ca
2+ [28]. We found that hTRPA1-L474A is activated
by lidocaine in a concentration-dependent manner
(Additional file 3, figure s3). These findings do not sug-
gest that Ca
2+ primarily induces activation of TRPA1 by
LAs.
Discussion
TRPV1 and TRPA1 have emerged as two principle
molecules for the perception of pungent and irritant
substances in nociceptive sensory neurons [29,30]. In
the meantime, an impressive number of agonists for
each receptor have meanwhile been identified. Along
with these discoveries, several distinct gating mechan-
isms have been revealed for both proteins. We could
now demonstrate that local anesthetics directly activate
TRPA1 and that they are thus common agonists of
TRPA1 and TRPV1 [15].
We previously reported that high concentrations of
LAs activate acrolein-sensitive (i.e. TRPA1-expressing)
dorsal root ganglion neurons derived from TRPV1-
knockout mice [15]. As demonstrated here, LAs indeed
activate both rodent and human TRPA1 heterologously
expressed in HEK293t cells. Lidocaine-evoked currents
were rapidly reversible upon washout of lidocaine,
displayed a clear concentration-dependency, were
blocked by the TRPA1-agonist HC030031 and were not
observed in non-transfected HEK293t cells. Thus there
is little doubt that the lidocaine-evoked inward currents
are due to a specific activation of TRPA1. Furthermore,
lidocaine-evoked TRPA1-currents display properties
similar to lidocaine-evoked TRPV1-currents [15]: 1.
When heterologously expressed in HEK293t cells, both
TRPV1 and TRPA1 are activated by lidocaine > 1 mM
and thus seem to have similar lidocaine-sensitivites
(IC50, rTRPA1:5 . 7±0 . 2m M ;I C 50, hTRPA1: 24.0 ± 0.6
mM; IC50, rTRPV1: ~ 12 mM). 2. Lidocaine not only acti-
vates both receptors, but also blocks both rodent
TRPA1 and TRPV1 in a concentration-dependent man-
ner. 3. Lidocaine seems to activate both TRPA1 and
TRPV1 via an intracellular pathway. However, there also
seem to be grave disparities between the mechanisms
leading to activation of TRPA1 and TRPV1 by LAs.
First, we found that repeated applications of 30 mM
lidocaine induce an incomplete and partially calcium-
dependent desensitization of TRPA1. In contrast, 30
mM lidocaine induced a strong but calcium-indepen-
dent desensitization of TRPV1 [15]. The mechanism
underlying these different patterns of lidocaine-induced
desensitization of TRPV1 and TRPA1 is unclear. Sec-
ond, we found that activation of TRPA1 by lidocaine
was significantly abrogated in the triple mutant
hTRPA1-3C. It is indeed established that reactive sub-
stances gate TRPA1 via a covalent and irreversible mod-
ification of these three intracellular cysteine residues
[24,25]. Lidocaine, however, does not offer a molecular
structure which would predict for such an effect.
Furthermore, lidocaine-evoked TRPA1-currents display
considerable faster current kinetics for both activation
and inactivation when compared to TRPA1-currents
evoked by the reactive agonists mustard oil and acrolein
(Figure 1A). This fact could suggest that additional
mechanisms, which are distinct from the covalent modi-
fication of cysteine residues,a r ec r u c i a l l yi n v o l v e di n
LA-evoked activation of TRPA1. We found that LAs are
also likely to interact with transmembrane region 5
(TM5) and that this interaction readily explains the spe-
cies-specific differences between rodent and human
TRPA1 with regard to current properties of lidocaine-
evoked currents, i.e. rodent but not human TRPA1 dis-
play a resurging current following washout of the LA.
While the same interaction was previously demonstrated
for menthol and the general anesthetic propofol, only
menthol seems to specifically interact with residues
within TM5 to actually gate TRPA1 [23,31]. Similar to
what we recently demonstrated for propofol [31], lido-
caine still activates the menthol-insensitive mutant
mTRPA1-S876V/T877L. Regarding TRPV1, we have
convincing evidence that LAs activate TRPV1 by
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binding domain and that this process requires an inter-
action of phosphatidylinositol 4,5-biphosphate (PI(4,5)
P2) with the proximal C-terminal TRP domain of
TRPV1 [15]. Neither of these two mechanisms can be
applied on TRPA1 as it lacks both, a vanilloid-binding
domain and a TRP domain within the proximal C-ter-
minus [32]. However, TRPA1 can be directly activated
by phospholipase C and also seems to be regulated by
PI(4,5)P2 [33-35]. As judged from the existing literature
however, the regulatory role of this signaling pathway
seems to apply for most TRPA1-agonists and would
thus not specifically apply for the effects evoked by LAs.
As was previously reported by Karashima and colleagues
[35], we also found that modulators of this pathway
such as the PLC-blocker U73122 and the phosphatidyli-
nositol 4-kinase blocker phenylarsine oxide directly gate
TRPA1 and therefore impede a thorough characteriza-
tion of these mechanisms on TRPA1 (data not shown,
[35]). Nonetheless, PLC-PI(4,5)P2-signaling should be
taken into regard in future studies which aim to identify
common intracellular regulators of TRPA1 and TRPV1.
In a clinical perspective, this study complements a
growing evidence that most general and local anes-
thetics as well as some analgesics activate or sensitize
nociceptors via TRPA1 and/or TRPV1 [15,31,36-39].
Systemically applied substances, like general anesthetics
and analgesics could employ TRPA1 to regulate or pro-
mote post-operative pain and inflammation. For exam-
ple, a recent study suggested that TRPA1 plays an
important role for airway inflammation and hyperreac-
tivity in a mouse model for asthma [40]. Accordingly,
TRPA1-activating volatile anesthetics were demonstrated
to exert direct effects on bronchial dilatation in a
TRPA1-dependent manner [39]. Moreover, a reactive
metabolite of acetaminophen (N-acetyl-p-benzo-quino-
neimine) activates TRPA1 and induces a TRPA1-depen-
dent airway inflammation after systemic application of
acetaminophen in a therapeutic dosage [41]. On the
other hand, although local anesthetics are only locally
applied, their concentrations should be sufficient to
evoke a strong activation of both TRPA1 and TRPV1.
When applied intrathecally, LAs can evoke a release of
both glutamate and neuropeptides like CGRP from cen-
tral nerve terminals expressing TRPA1 and/or TRPV1
and thus regulate spinal nociceptive signalling and ulti-
mately promote “central sensitization” [11,15]. When
applied intradermally or into the perineural space, LAs
can promote the development of neurogenic inflamma-
tion by inducing a release of neuropeptides, thus sensi-
tizing peripheral nociceptive signalling [12,15].
Furthermore, TRPA1 and TRPV1 display a significant
co-expression in nociceptive sensory neurons [42]. It is
therefore tempting to speculate about a high
susceptibility of these neurons to undergo LA-evoked
neurotoxicity as result of TRPV1 and TRPA1-activation.
Although conclusive in vivo studies which address or
confirm the proposed effects of general and local anes-
thetics are yet lacking, it is well conceivable that TRPV1
and TRPA1 antagonists will prove to be efficient for
prevention and treatment of some unwanted effects
which are likely to be induced by anesthetic substances
that activate TRP-channels.
Methods
Mutagenesis and Heterologous Expression
Mutagenesis of human and mouse TRPA1 was per-
formed as described previously [43]. Human TRPA1
cDNA was obtained from Dr. Paul Heppenstall (EMBL,
Monterotondo, Italy), constructs of mouse and human
TRPA1 were obtained from Dr. Ardem Patapoutian
(The Scripps Research Institute, La Jolla, USA) and all
other cDNAs were obtained from Dr. David Julius
(UCSF, San Francisco, USA). All constructs were con-
firmed by DNA sequencing. HEK293t cells were trans-
fected as described previously [43]. Briefly, HEK293t
cells were transfected with plasmids of rat, mouse or
human TRPA1 (5 μg) or TRPM8 (2 μg) along with a
reporter plasmid (CD8-pih3m; 1 μg) by the calcium
phosphate precipitation method. After incubation for
12-15 h, the cells were replated in 35 mm culture dishes
and used for experiments within 2-3 days. Transfection-
positive cells were identified by immunobeads (anti-CD8
Dynabeads; Dynal Biotech).
Patch Clamp Recordings
Whole cell voltage clamp recordings currents were
acquired with an Axopatch 200B amplifier (Axon Instru-
ments/Molecular Devices, Sunnyvale, CA). Currents
were filtered at 1 kHz and sampled at 5 kHz. Electrodes
were pulled from borosilicate glass tubes (TW150F-3;
World Precision Instruments, Berlin, Germany) and
h e a t - p o l i s h e dt og i v ear e s i s t a n c eo f1 . 5 -2 . 0M Ω.T h e
standard external solution contained (in mM): 140
NaCl, 5 KCl, 2 CaCl2,2M g C l 2, 10 HEPES, 10 Glucose
(pH 7.4 adjusted with tetramethylammonium hydroxide
(TMA-OH)). In Ca
2+-free solutions, CaCl2 was replaced
by 5 mM EGTA. The internal solution contained (in
mM) 140 KCl, 2 MgCl2, 5 EGTA and 10 HEPES (pH
7.4 adjusted with KOH). If not noted otherwise, cells
were held at -60 mV. All recordings were performed at
room temperature. Solutions were applied with a polyte-
trafluorethylen glass multiple-barrel perfusion system.
The cold stimulus for experiments on TRPM8 was
delivered using a multi-channel, gravity-driven system
incorporating rapid-feedback temperature control. In
this system, a platinum-covered glass capillary, posi-
tioned < 100 μm from the cell under study, was used as
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Instruments) was used for acquisition and off-line
analysis.
Chemicals
Lidocaine, procaine, mepivacaine (all Sigma-Aldrich) and
QX-314 (Biotrend, Colonia, Germany) were directly dis-
solved in the extracellular solution. If not noted other-
wise, the pH-values of all LA-solutions were corrected to
pH 7.4 with TMA-OH. Capsaicin (Sigma-Aldrich) was
dissolved in absolute ethanol to give a stock solution of 1
mM. Mustard oil, carvacrol (Sigma-Aldrich) and HC-
030031 (Biotrend, Colonia, Germany) were dissolved in
DMSO to give stock solutions of 100 mM.
Statistical analysis
Calculations for statistical comparisons were performed
with the Statistica software package 7.0 (Statsoft, Tulsa,
USA) or with the Origin 7.0 software package (Origi-
nLab Corporation, Northampton, USA). Tests used are
stated in the text or in figure legends. P values < 0.05
were considered statistically significant. * denominates p
< 0.05, ** denominates p < 0.01, *** denominates p <
0.001 and n.s. denominates a non-significant finding. All
data are given as mean ± SEM.
Additional material
Additional file 1: MO-induced currents of hTRPA1-WT are
desensitized by lidocaine. 10 mM Lidcoacine was co-applied with 100
μM MO during the steady-state phase of MO-evoked currents. Note that
lidocaine first induced an additional activation followed by a
desensitization. Cells were held at -60 mV.
Additional file 2: MO-induced currents of mTRPA1-S876V/T877L are
not blocked by lidocaine. 30 mM Lidcoacine was co-applied with 100
μM MO during the steady-state phase of MO-evoked currents and
experiments were performed in Ca2+-free extracellular solution to
minimize desensitization. Note the the resurging currents after washout
of lidocaine. Cells were held at -60 mV.
Additional file 3: Lidocaine-induced currents of the calcium-
insensitive mutant hTRPA1-L474A. 10 mM (149 ± 23 pA, n = 7) or 30
mM (223 ± 67, n = 6) lidcoacine were applied for ~20s on separate cells
to minimize desensitization. Note the resurging current after washout of
30 mM lidocaine. Cells were held at -60 mV.
List of abbreviations
LA: local anesthetic; TRP: transient receptor potential; HEK293t cell: human
embryonic kidney cell 293t; mTRPA1: mouse TRPA1; hTRPA1: human TRPA1;
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